{
  "id": "56c1f01def6e394741000045",
  "type": "factoid",
  "question": "Orteronel was developed for treatment of which cancer?",
  "ideal_answer": "Orteronel was developed for treatment of castration-resistant prostate cancer.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/24799061",
    "http://www.ncbi.nlm.nih.gov/pubmed/24418642",
    "http://www.ncbi.nlm.nih.gov/pubmed/25537627",
    "http://www.ncbi.nlm.nih.gov/pubmed/25701170",
    "http://www.ncbi.nlm.nih.gov/pubmed/25624429",
    "http://www.ncbi.nlm.nih.gov/pubmed/25264242",
    "http://www.ncbi.nlm.nih.gov/pubmed/21978946",
    "http://www.ncbi.nlm.nih.gov/pubmed/26150028",
    "http://www.ncbi.nlm.nih.gov/pubmed/24100689"
  ],
  "snippets": [
    {
      "text": "Pooled-analysis was also performed, to assess the effectiveness of agents targeting the androgen axis via identical mechanisms of action (abiraterone acetate, orteronel).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26150028",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The experimental interventions tested in these studies were enzalutamide, ipilimumab, abiraterone acetate, orteronel and cabazitaxel. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26150028",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Pooled analysis of androgen synthesis inhibitors orteronel and abiraterone resulted in significantly increased overall and progression-free survival for anti-androgen agents, compared to placebo (hazard ratio for death: 0.76, 95% CI 0.67 to 0.87, P<0.0001; hazard ratio for radiographic progression: 0.7, 95% CI 0.63 to 0.77, P<0.00001). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26150028",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Agents targeting the androgen axis (enzalutamide, abiraterone, orteronel) significantly prolonged rPFS, compared to placebo. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26150028",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25701170",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND: Orteronel is an investigational, partially selective inhibitor of CYP 17,20-lyase in the androgen signalling pathway, a validated therapeutic target for metastatic castration-resistant prostate cancer. We assessed orteronel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25701170",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "NTERPRETATION: In chemotherapy-naive patients with metastatic castration-resistant prostate cancer, radiographic progression-free survival was prolonged with orteronel plus prednisone versus placebo plus prednisone.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25701170",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "On the basis of these and other data, orteronel is not undergoing further development in metastatic castration-resistant prostate cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25701170",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25624429",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "This study examined orteronel in patients with metastatic castration-resistant prostate cancer that progressed after docetaxel therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25624429",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Longer rPFS and a higher PSA50 rate with orteronel-prednisone indicate antitumor activity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25624429",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A phase 1 multiple-dose study of orteronel in Japanese patients with castration-resistant prostate cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25537627",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We evaluated the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor effect of orteronel with or without prednisolone in Japanese patients with castration-resistant prostate cancer (CRPC).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25537627",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Orteronel at doses up to 400 mg BID was tolerable in Japanese CRPC patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25537627",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Orteronel for the treatment of prostate cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24799061",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Orteronel (also known as TAK-700) is a novel hormonal therapy that is currently in testing for the treatment of prostate cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24799061",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Orteronel is a nonsteroidal, selective inhibitor of 17,20-lyase that was recently in phase 3 clinical development as a treatment for castration-resistant prostate cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25264242",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Early reports of clinical studies demonstrate that orteronel treatment leads to reduced prostate-specific antigen levels, a marker of prostate cancer tumor burden, and more complete suppression of androgen synthesis than conventional androgen deprivation therapies that act in the testes alone.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24799061",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21978946",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Therefore, (+)-3c (termed orteronel [TAK-700]) was selected as a candidate for clinical evaluation and is currently in phase III clinical trials for the treatment of castration-resistant prostate cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21978946",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We assessed orteronel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25701170",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Orteronel is a nonsteroidal, selective inhibitor of 17,20-lyase that was recently in phase 3 clinical development as a treatment for castration-resistant prostate cancer. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25264242",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24418642",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "On the basis of these and other data, orteronel is not undergoing further development in metastatic castration-resistant prostate cancer.FUNDING: Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25701170",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "New androgen biosynthesis inhibitors have been developed, such as orteronel (TAK-700), but also new antiandrogens (enzalutamide, ARN-509, ODM-201) or even agents with a dual mechanism of action (galeterone). In this review the development of new hormonal therapies following the arrival of abiraterone for the treatment of prostate cancer will be summarized.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24100689",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "http://www.disease-ontology.org/api/metadata/DOID:162"
  ],
  "exact_answer": "castration-resistant prostate cancer"
}